Adjuvant Gemcitabine and Nab-Paclitaxel Misses the Target in Pancreas Adenocarcinoma: Or Did an Effective Therapy Fall to the Definition of Recurrence?-Reference-Cited by-同舟云学术

Adjuvant Gemcitabine and Nab-Paclitaxel Misses the Target in Pancreas Adenocarcinoma: Or Did an Effective Therapy Fall to the Definition of Recurrence?

Published:2023-04-10 Issue:11 Volume:41 Page:1972-1975
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Manji Gulam A.¹²³^ORCID

Affiliation:

1. Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY

2. New York Presbyterian Hospital, Herbert Irving Pavilion, New York, NY

3. Herbert Irving Comprehensive Cancer Center, New York, NY

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.23.00039

Reference14 articles.

1. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

2. nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

3. Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection

4. Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial;LANCET GASTROENTEROL;2024

2. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial;The Lancet Gastroenterology & Hepatology;2024-08

3. Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations;The Lancet Oncology;2024-07

4. Initial chemotherapy option for pancreatic ductal adenocarcinoma in patients with adequate performance status;Journal of Pancreatology;2023-09-27

5. Reply to C. Springfeld et al;Journal of Clinical Oncology;2023-09-01